Efficacy and safety of TACE combined with lenvatinib and PD-1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study

doi:10.1002/cam4.5880

科研成果详情

题名	Efficacy and safety of TACE combined with lenvatinib and PD-1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study
作者	Wang, Wei-Jun 1; Liu, Zong-Han 1; Wang, Kang 1; Yu, Hong-Ming 1; Cheng, Yu-Qiang 1; Xiang, Yan-Jun2; Feng, Jin-Kai 1; Zhou, Li-Ping 1; Zhou, Hong-Kun 3; Pan, Wei-Wei 4,5; Guo, Wei-Xing 1; Shi, Jie 1; Cheng, Shu-Qun 1,4
发表日期	2023-05
发表期刊	Cancer medicine 影响因子和分区
语种	英语
原始文献类型	Journal Article
关键词	combination therapy hepatocellular carcinoma (HCC) lenvatinib programmed death-1 recurrent transarterial chemoembolization (TACE)
其他关键词	RENAL-CELL CARCINOMA ; HEPATOCELLULAR-CARCINOMA ; TRANSARTERIAL CHEMOEMBOLIZATION ; MANAGEMENT ; CANCER ; IMMUNOTHERAPY ; PEMBROLIZUMAB ; METAANALYSIS ; COMBINATION ; EXPRESSION
摘要	There is no consensus on the optimal regimen for unresectable recurrent hepatocellular carcinoma (HCC), so this retrospective study aimed to evaluate the efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib and PD-1 inhibitors (T-L-P) versus TACE combined with lenvatinib (T-L) or TACE alone., Data were collected from 204 patients with unresectable recurrent HCC who received T-L-P, T-L, or TACE alone at three medical centers from January, 2019 to December, 2020 for analysis. The survival outcomes, tumor response, and adverse events were compared between three groups, and risk factors were further investigated., The median overall survival in the T-L-P, T-L, and TACE alone groups were not reached, 25.6, and 15.7 months, respectively (p < 0.001). The median progression-free survival in the T-L-P, T-L, and TACE alone groups were 24.1, 17.3, and 13.7 months, respectively (p < 0.001). The best objective response rate in the T-L-P, T-L, and TACE alone groups were 70.4%, 48.9%, and 42.5%, respectively. The best disease control rate in the T-L-P, T-L, and TACE alone groups were 100.0%, 97.8%, and 87.5%, respectively. There was no significant difference between the T-L-P and T-L groups for Grade 3/4 adverse events., T-L-P regimen was safe and superior to T-L or TACE alone in improving survival for unresectable recurrent HCC patients.
资助项目	Clinical Research Plan of SHDC [SHDC2020CR1004A]; National Natural Science Foundation of China [81770630]; Science and Technology Commission Foundation of Shanghai Municipality [19411967300]; State Key Program of National Natural Science Foundation of China [81730097]; National Key Research and Development Program of China [2022YFC2503700]
出版者	WILEY
ISSN	2045-7634
卷号	12 期号:10 页码:11513-11524
DOI	10.1002/cam4.5880
页数	12
WOS类目	Oncology
WOS研究方向	Oncology
WOS记录号	WOS:000962184200001
收录类别	PUBMED ; SCIE ; SCOPUS
在线发表日期	2023-03
URL	查看原文
PubMed ID	36999793
SCOPUSEID	2-s2.0-85151951755
通讯作者地址	[Cheng, Shu-Qun]Eastern Hepatobiliary Surgery Hospital,Second Military Medical University,Shanghai, 225 Changhai Road,Shanghai,200433,China
Scopus学科分类	Oncology;Radiology, Nuclear Medicine and Imaging;Cancer Research
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/174201
专题	附属第一医院
通讯作者	Cheng, Shu-Qun
作者单位	1.Department of Hepatic Surgery VI,Eastern Hepatobiliary Surgery Hospital,Second Military Medical University,Shanghai,China; 2.Department of Hepatobiliary Surgery,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China; 3.The First Hospital of Jiaxing Affiliated Hospital of Jiaxing University,Jiaxing University,Jiaxing,China; 4.Department of Cell Biology,College of Medicine,Jiaxing University,118 Jiahang Road,Jiaxing,China; 5.G60 STI Valley Industry & Innovation Institute,Jiaxing University,Jiaxing University,Jiaxing,China
推荐引用方式 GB/T 7714	Wang, Wei-Jun,Liu, Zong-Han,Wang, Kang,et al. Efficacy and safety of TACE combined with lenvatinib and PD-1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study[J]. Cancer medicine,2023,12(10):11513-11524.
APA	Wang, Wei-Jun., Liu, Zong-Han., Wang, Kang., Yu, Hong-Ming., Cheng, Yu-Qiang., ... & Cheng, Shu-Qun. (2023). Efficacy and safety of TACE combined with lenvatinib and PD-1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study. Cancer medicine, 12(10), 11513-11524.
MLA	Wang, Wei-Jun,et al."Efficacy and safety of TACE combined with lenvatinib and PD-1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study".Cancer medicine 12.10(2023):11513-11524.